News

Study reveals ‘complete mental health’ among cancer survivors


 

Photo by Rhoda Baer

Nurse bandaging chemotherapy patient

New research suggests cancer survivors are just as likely as people without a history of cancer to have complete mental health (CMH), which is defined as “optimal functioning” and the “absence of psychopathology.”

In a study of nearly 11,000 Canadians, 77.5% of cancer survivors and 76.8% of people with no cancer history had CMH.

As for patients who were battling cancer at the time of the study, 66.1% had CMH.

Esme Fuller-Thomson, PhD, and Keri West, both of the University of Toronto in Canada, conducted this research and reported the findings in Aging & Mental Health.

“Cancer patients were doing much better than we had expected,” Dr. Fuller-Thomson said. “Two-thirds met our very stringent criteria for complete mental health . . . . The news for cancer survivors was even better, with three-quarters living in complete mental health, which is a prevalence comparable to that of individuals with no cancer history.”

This study included a nationally representative sample of Canadian community dwellers age 50 and older. Subjects had current cancer (n=438), previous cancer (n=1174), or no cancer history (n=9279).

Data were obtained from Statistics Canada’s 2012 Canadian Community Health Survey-Mental Health.

To meet criteria for CMH, subjects had to have all of the following:

  • Absence of mental illness, addictions, and suicidal thoughts in the past year
  • Almost daily happiness or life satisfaction in the past month
  • Psychosocial well-being.

The prevalence of CMH was 77.5% in cancer survivors and 76.8% in subjects who had never had cancer. Both were significantly higher than the 66.1% prevalence of CMH in current cancer patients (P<0.001).

In a multivariable model adjusted for demographics, current cancer patients had 45% lower odds of CMH compared to subjects with no cancer history (odds ratio [OR]=0.55). The odds of CMH were comparable for cancer survivors and those without a history of cancer (OR=0.98).

The researchers also conducted a multivariable analysis in which they adjusted for “all relevant factors,” which included demographics as well as adverse childhood events, socioeconomic status, health variables, lifetime mental illness, etc.

In this analysis, current cancer patients had 37% lower odds of CMH than subjects with no cancer history (OR=0.63). And cancer survivors had comparable odds of CMH as those with no cancer history (OR=1.06).

The researchers identified several factors that were associated with CMH in the population affected by cancer.

“Among those with former or current cancer, the odds of complete mental health were higher for women, white, married, and older respondents, as well as those with higher income and those who did not have disabling pain nor functional limitations,” West said.

“We found that earlier difficulties cast a long shadow. Those who had been physically abused during their childhood and those who had ever had depression or anxiety disorders were less likely to be in complete mental health.”

West and Dr Fuller-Thomson emphasized that these results are only correlational, and it is impossible to determine causality due to the cross-sectional and observational nature of the study.

The pair also said future longitudinal research is needed to improve understanding of what pathways improve resilience and recovery among cancer patients.

Recommended Reading

First CAR T-cell therapy approvals bolster booming immunotherapy market
MDedge Hematology and Oncology
FDA puts partial hold on trial of vascular agent for AML, MDS
MDedge Hematology and Oncology
FDA grants orphan designation to DHODH inhibitor for AML
MDedge Hematology and Oncology
Combo treatment yields MRD-negative remissions in CLL
MDedge Hematology and Oncology
Combo produces high response rate in CLL
MDedge Hematology and Oncology
AMP publishes report on DNA variants in CMNs
MDedge Hematology and Oncology
Inhibitor receives orphan designation for AML
MDedge Hematology and Oncology
Role of SES in childhood cancer survival disparities
MDedge Hematology and Oncology
Partial hold placed on trial of drug for AML, MDS
MDedge Hematology and Oncology
Access to care drives disparity between urban, rural cancer patients
MDedge Hematology and Oncology